How to Start a TRT Telehealth Business, Legally

The controlled-substance layer, precisely

The baseline is the Ryan Haight Act: prescribing controlled substances via telemedicine generally requires a prior in-person evaluation unless an exception applies. The operative exception as of September 2026 is the Fourth Temporary Extension of the COVID-era telemedicine flexibilities (published December 31, 2025, in the Federal Register), which permits prescribing Schedule II-V substances, testosterone included, on a real-time, two-way audio-video encounter with no prior in-person exam, for a legitimate medical purpose in the usual course of practice, through December 31, 2026. Audio-only encounters do not qualify for initiating testosterone; the audio-only carve-out covers only certain opioid-use-disorder medications.

What comes next is drafted but not final: DEA's special-registration framework (proposed January 2025) would put Schedule III telemedicine prescribing under a dedicated registration, with per-state telemedicine registrations, audio-video requirements, patient photo-ID verification, prescription-monitoring checks, special notations on prescriptions, and a separate platform registration for covered telemedicine companies. The final rule went to OMB review in August 2026 with publication forecast for November 2026. Two planning consequences follow: build your program to that framework's shape now (it is the direction of travel), and calendar the hard date: if nothing final issues, the current flexibilities lapse January 1, 2027, and the in-person default returns until a new instrument exists. A TRT program without a plan for that date does not have a plan.

The federal layer in one sourced sentence: through December 31, 2026, a licensed clinician may initiate TRT by real-time audio-video telemedicine with no prior in-person exam (Fourth Temporary Extension, 90 FR 61301), and the permanent special-registration framework now in final review is what your program should already be shaped like.

The state layer: fifty overlays, not one rule

The federal flexibility is a floor, not a license: state telehealth-prescribing rules, medical practice acts, and in some states in-person or established-relationship requirements apply independently, and a TRT program's serviceable-state map is the intersection of federal permission, state rules, clinician licensure, and pharmacy coverage. This is the same state-matrix discipline our state-prescribing guide describes, with the controlled-substance overlay making the per-state homework heavier and less optional.

Practically: launch state-gated from day one (the storefront blocks unserved states in the product, not the fine print), sequence states by clarity rather than by market size, and assign the map to someone whose job includes re-checking it, because both layers move.

The clinical model TRT actually requires

TRT is lab-driven medicine: credible programs are built around baseline laboratory work, individualized clinical evaluation on real-time video, and ongoing monitoring, with every decision (whether to treat, what to prescribe, when to adjust, when to stop) made by the licensed clinician for that patient. The lab requirement shapes operations: your patient journey includes blood draws, which means lab-network integrations or local draw sites, result routing to the clinician, and follow-up cadences the clinical team owns.

The marketing discipline is stricter here than anywhere outside GLP-1s: no outcome promises, no optimization guarantees, no framing that presumes a prescription before an evaluation, and program pricing that never bundles the expectation of a controlled substance. Patients who don't qualify must be a designed-for outcome; in this category, the no's are load-bearing.

The enforcement record, and what it teaches

The cases that define this category's risk are recent and instructive. In November 2025, a federal jury convicted the CEO and clinical president of Done Global, a subscription telehealth company, in the first criminal drug-distribution prosecution of a telehealth platform: the model pressured prescribing of Schedule II stimulants through subscription mechanics and thin evaluations. It was not a TRT case, and it is the TRT lesson anyway: subscription pressure on controlled-substance prescribing is criminal territory, not a growth tactic. The 2026 national health-care fraud takedown included an individual physician charged over thousands of testosterone and other prescriptions issued without exams or records: the no-real-evaluation pattern, prosecuted directly.

And in July 2026, the FTC and state partners sued Hims & Hers over health-data sharing with ad platforms and subscription-cancellation practices, a reminder that the men's-health category's other legal surfaces (privacy plumbing, honest billing, cancellation as easy as signup) are enforced as aggressively as the prescribing rules. A TRT program's compliance build covers all of it: clinical independence structurally protected, evaluations that are real, tracking pixels configured for health data, and subscriptions that survive a regulator's cancellation test.

• Never tie clinician pay or program mechanics to prescription volume: that is the Done lesson, criminally enforced
• Every patient individually evaluated on real-time video, with labs, records, and monitoring owned by clinicians
• State-gate in the product; sequence states by regulatory clarity
• Privacy and billing surfaces are enforcement surfaces: pixel hygiene, honest subscriptions, findable cancellation
• Calendar December 31, 2026: the current federal instrument expires, and the final special-registration rule lands around then

Supply, structure, and economics

Supply runs through licensed pharmacies as with any Rx program, with the controlled-substance chain adding dispensing and record obligations on the pharmacy side; compounded testosterone formulations exist under 503A postures and carry the same written-legal-basis diligence as any compounded product. Structure is the standard triangle with the MSO chassis for non-clinician owners, and nothing about Schedule III changes who may own what: clinicians own the medicine, your company owns the program.

The economics resemble the hormone category generally: lab-inclusive onboarding, subscription care with monitoring visits, and retention that tracks clinical follow-through rather than marketing. Model it with the same honesty as any program (contribution per month times tenure, acquisition subtracted), and price the compliance build into the plan: the controlled-substance layer is real operating cost, and it is also the moat, because programs that do it right operate in a category most founders bounce off.

Where EmbedCare fits, stated carefully: the platform operates the general stack this guide keeps referencing (50-state clinical network with independence structurally protected, storefronts to certification standards, owned pharmacy supply, retention machinery), and hormone care lines run where state and federal rules support them. The controlled-substance workflows this page describes (video-visit modality, identity verification, monitoring cadences, the special-registration readiness) are exactly what to diligence with any platform, ours included; a demo conversation for a TRT program starts with that checklist, which is how it should start everywhere.